353P Prognostic role of metastatic sites in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab
Silvia Camera(Vita-Salute San Raffaele University), S. Bozzarelli(IRCCS Humanitas Research Hospital), Oluseyi Abidoye(Mayo Clinic), M. Rimini(IRCCS Ospedale San Raffaele), Francesca Salani(Scuola Superiore Sant'Anna), Anna Saborowski(Medizinische Hochschule Hannover), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), L. Rimassa(IRCCS Humanitas Research Hospital), Jessica Lucchetti(Campus Bio Medico University Hospital), Mario Domenico Rizzato(University of Padua), Federico Rossari(Vita-Salute San Raffaele University), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Chiara Gallio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), M. Persano, J.W. Kim(Seoul National University Bundang Hospital), Frederik Peeters, Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Tatsunari SATAKE(National Cancer Center Hospital East)
Cited by 0
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
|British Journal of Cancer|2020|350
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
|The Lancet Oncology|2022|268
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
|The Oncologist|2014|103